Angiotensin II type 2 receptor gene polymorphisms in cardiovascular disease

Considerable progress in our understanding of the role of the angiotensin II type 2 (AT 2 ) receptor in the development of cardiac hypertrophy and coronary artery disease has been achieved using in vitro and in vivo animal models. Our understanding in humans, however, has been hindered by the lack o...

Full description

Bibliographic Details
Main Author: Anthony J Balmforth
Format: Article
Language:English
Published: Hindawi - SAGE Publishing 2010-03-01
Series:Journal of the Renin-Angiotensin-Aldosterone System
Online Access:https://doi.org/10.1177/1470320309347782
id doaj-a92d700afdbf4f5490800ff4ba803803
record_format Article
spelling doaj-a92d700afdbf4f5490800ff4ba8038032021-05-02T21:31:39ZengHindawi - SAGE PublishingJournal of the Renin-Angiotensin-Aldosterone System1470-32032010-03-011110.1177/1470320309347782Angiotensin II type 2 receptor gene polymorphisms in cardiovascular diseaseAnthony J BalmforthConsiderable progress in our understanding of the role of the angiotensin II type 2 (AT 2 ) receptor in the development of cardiac hypertrophy and coronary artery disease has been achieved using in vitro and in vivo animal models. Our understanding in humans, however, has been hindered by the lack of availability of specific AT 2 receptor agonists and antagonists suitable for human study. Nevertheless, an alternative approach involving genotyping humans for a functional polymorphism within the AT 2 receptor gene (—1332G/A) has been used in several association studies to elucidate the pathogenic role of the AT 2 receptor in cardiovascular disease. Both the A allele and the G allele have independently been associated with left ventricular remodelling. However, the methods of measuring left ventricular mass, sodium balance, age and degree of remodelling appear to influence the outcome. An association of carriers of the G allele and premature coronary artery disease has also been established, particularly in males presenting with stenotic atherosclerosis requiring revascularisation. At the molecular level, it remains unclear as to whether carriers of the G allele express more or fewer AT 2 receptors when compared to carriers of the A allele. Consequently, it is presently not possible to definitively interpret the role of the AT 2 receptor in human cardiovascular disease from these association studies.https://doi.org/10.1177/1470320309347782
collection DOAJ
language English
format Article
sources DOAJ
author Anthony J Balmforth
spellingShingle Anthony J Balmforth
Angiotensin II type 2 receptor gene polymorphisms in cardiovascular disease
Journal of the Renin-Angiotensin-Aldosterone System
author_facet Anthony J Balmforth
author_sort Anthony J Balmforth
title Angiotensin II type 2 receptor gene polymorphisms in cardiovascular disease
title_short Angiotensin II type 2 receptor gene polymorphisms in cardiovascular disease
title_full Angiotensin II type 2 receptor gene polymorphisms in cardiovascular disease
title_fullStr Angiotensin II type 2 receptor gene polymorphisms in cardiovascular disease
title_full_unstemmed Angiotensin II type 2 receptor gene polymorphisms in cardiovascular disease
title_sort angiotensin ii type 2 receptor gene polymorphisms in cardiovascular disease
publisher Hindawi - SAGE Publishing
series Journal of the Renin-Angiotensin-Aldosterone System
issn 1470-3203
publishDate 2010-03-01
description Considerable progress in our understanding of the role of the angiotensin II type 2 (AT 2 ) receptor in the development of cardiac hypertrophy and coronary artery disease has been achieved using in vitro and in vivo animal models. Our understanding in humans, however, has been hindered by the lack of availability of specific AT 2 receptor agonists and antagonists suitable for human study. Nevertheless, an alternative approach involving genotyping humans for a functional polymorphism within the AT 2 receptor gene (—1332G/A) has been used in several association studies to elucidate the pathogenic role of the AT 2 receptor in cardiovascular disease. Both the A allele and the G allele have independently been associated with left ventricular remodelling. However, the methods of measuring left ventricular mass, sodium balance, age and degree of remodelling appear to influence the outcome. An association of carriers of the G allele and premature coronary artery disease has also been established, particularly in males presenting with stenotic atherosclerosis requiring revascularisation. At the molecular level, it remains unclear as to whether carriers of the G allele express more or fewer AT 2 receptors when compared to carriers of the A allele. Consequently, it is presently not possible to definitively interpret the role of the AT 2 receptor in human cardiovascular disease from these association studies.
url https://doi.org/10.1177/1470320309347782
work_keys_str_mv AT anthonyjbalmforth angiotensiniitype2receptorgenepolymorphismsincardiovasculardisease
_version_ 1721487234527395840